Our immune cells learn the behavioral patterns of certain infections in two basic ways. First, by passing the actual infection; it's like learning to fight at the front, and every experience comes with a big price. The second is by grafting; By injecting a harmless copy of the microbe into the body, our immune cells are introduced to the enemy and recognize him each subsequent encounter. In some cases, immunity through infection may be more educational and powerful; but vaccine immunity is more advantageous because it is much less risky.
Our bodies cannot remember certain pathogens to fight them again. Fortunately, the coronavirus is not one of them. Both curing the disease and vaccination provide very strong protection against the disease.
The opinion of the experts on this issue is as follows: Never choose to have the disease over vaccination. Any encounter you enter unprotected with the coronavirus is a double gamble. No matter how healthy you are, you cannot predict the effect of the virus on your body.
This has historically been the whole purpose of vaccination: to experience the infection in a much more comfortable and protected package. Some studies have shown that the immunity of those who have had the disease and those who have been vaccinated are at similar levels: So why should we choose the risky route?
Passing the disease teaches a broader lesson about our bodies. The body has information about the entire virus. Most of the Covid vaccines target the spike protein of the virus. At the same time, since the coronavirus is an airborne virus, the upper respiratory tract of people who have the disease is more protected against the virus. Typical covid vaccines, on the other hand, produce multi-purpose antibodies in the blood and circulatory system rather than in the arm muscles. This ensures that in vaccinated bodies, the virus cannot fully prevent its initial entry into the body.
In addition to all these, infection carries the risk of hospitalization, intensive care, long-term discomfort and death. In addition, there is solid data that determines the strength of immunity that will occur after the severity of the infection. Finally, each infected person also poses an added hazard as a public health threat, as they are a serious carrier of the virus.
There is not yet an agreed-upon answer to when people who have had the disease should be vaccinated. While those who have had the disease in the USA can receive 2 doses of vaccine, 1 dose of vaccine is sufficient for people who have had the disease in France. In cases where the population is willing but not enough vaccines, vaccination priority of survivors seems to be delayed a little longer. However, if there are enough vaccines and a certain time has passed since the disease, the administration of both doses of the vaccine stands out as the safest and optimum way for now.
